0001867096-23-000050.txt : 20230329
0001867096-23-000050.hdr.sgml : 20230329
20230329165351
ACCESSION NUMBER: 0001867096-23-000050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230327
FILED AS OF DATE: 20230329
DATE AS OF CHANGE: 20230329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fairley Ricki Louise
CENTRAL INDEX KEY: 0001971350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 23775917
MAIL ADDRESS:
STREET 1: XERIS BIOPHARMA HOLDINGS, INC.
STREET 2: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 N. LASALLE STREET, SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
wf-form4_168012321668743.xml
FORM 4
X0407
4
2023-03-27
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001971350
Fairley Ricki Louise
C/O XERIS BIOPHARMA HOLDINGS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
1
0
0
0
0
Common Stock
2023-03-27
4
A
0
85000
0
A
85000
D
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
/s/ Beth Hecht as Attorney-in-Fact
2023-03-29